Month: August 2021

Report on the first half year of 2021for ROCKWOOL International A/SRelease no. 19 – 2021to Nasdaq Copenhagen 18 August 2021 Broad based growth, with strong sales and earnings in an upbeat market HighlightsH1 2021 sales reached 1 449 MEUR, an increase of 20 percent in local currencies and 18 percent in reported figures.Sales in Q2 2021 reached 778 MEUR, a growth of 35 percent in local currencies compared to Q2 2020. Strong market rebound with high volume growth.Compared to 2019, sales increased 11 percent in H1 2021 and 15 percent in Q2 2021 in local currencies.EBITDA in H1 2021 reached 299 MEUR, with a 20.7 percent EBITDA margin, up 2.1 percentage points from H1 2020. EBITDA in Q2 2021 reached 160 MEUR, with a 20.6 percent EBITDA margin, up 2.8 percentage points from Q2 2020. EBIT in H1 2021 increased 46 percent to 201 MEUR, with...

Release no. 31/2021 A solid second quarter ”We are satisfied with the result for Q2 and the first 6 months overall. Columbus has reached the first milestones in executing the Focus23 strategy, comprising the re-organization of the company in a new customer focused matrix structure. It is time to unleash the full potential of our skilled employees, relevant end-to-end solutions and the increasing demand for digitalization services”, says CEO and President Søren Krogh Knudsen. Financial highlights for the period 1 January to 30 June 2021All numbers and comments in the H1 report are on the continued business, thus excluding the divested entities To-Increase and Baltics. Financial figuresDKKm Q2 2021 Q2 2020 ∆% H1 2021 H1 2020 ∆%Revenue reported 426 402 6% 847 859 -1%Foreign exchange -5 0 0% -4 0 0%Organic revenue 421 402 5% 843 859 -2%             EBITDA...

August 18, 2021Announcement no. 14Q2 2021 Report Highlights Solid revenue growth in the first half of 2021 In the first half of 2021, BioPorto’s revenue grew by 20% measured in USD and 11% when measured in DKK, driven by strong sales of antibodies and higher research use only (RUO) sales of The NGAL Test™ in the US. In the second quarter of 2021, revenue from antibodies was up 118% and RUO sales of The NGAL Test in the US increased 84% in USD and 68% in DKK. Enrollment in the US clinical trial of The NGAL Test continues; interim re sults expected end‐August 2021 Enrollment of patients in the study to support a De Novo 510(k) application for The NGAL Test for use in pediatrics has progressed well in the second quarter of 2021. During this period BioPorto also brought on board several new trial sites, contributing to further progress in...